Joshua Silverwood

The topline results found that rifasutenizol showed better safety and tolerability than the current standard of care.

Designed to treat end-stage liver disease, the company has been granted permission from the Spanish authorities to expand its EMERALD trial.

A previous study examining the SJP-001 compound found it was able to cut hangover symptoms such as headaches, nausea, and dizziness.

Aimed at patients who are ineligible to take part in other clinical trials due to their advanced stage ALS, the trial hopes to examine the impact of ibudilast.

Hot off the heels of the searing Darzi report that found UK healthcare woefully lacking in technological progress, the UK Government has announced new investments into the sector, but will it be enough to turn things around?

Research published by COTA alongside the Memorial Sloan Kettering Cancer Center found patients who start treatment within two weeks of diagnosis face worse outcomes than those who wait.

The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol therapies aren't working.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy (ADT). The sNDA application is based on positive results from the company's

The two studies of the company's engineered vascular tissue saw success with casualties in Ukraine and the US.

A report filed with a US authority discloses that a patient who suffered a severe adverse event during the trial has now died.